If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT01128686","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"","masked_caregiver":"","masked_investigator":"","masked_subject":"","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"None","acronym":"LAMGR","allocation":"","arm_groups":[{"arm_group_label":"CHB patients who started LAM as an initial antiviral treatment","arm_group_description":"CHB patients who started LAM as an initial antiviral treatment at least 5 years prior to this investigation","arm_type":""}],"assignment":"","brief_summary":"This is to evaluate the proportion of subjects who show good responses to LAM treatment in Korea.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Lamivudine(LAM) Good Responder Study","conditions":[{"DisplayValue":"Hepatitis B","DisplayValue_OneLinkTx":"","InternalValue":"CON_HEPATITIS_B","LookupValue":"Hepatitis B, Chronic","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:44:13","criteria":"Inclusion Criteria: 1.CHB or liver cirrhosis due to Hepatitis B virus who had started LAM between Jan 1, 2003 and Dec 31, 2004 and maintained LAM at least 6 months 2.HBsAg positive at least for 6 months at the beginning of observation 3.HBV DNA positive before LAM administration 4.Subjects with certain pre-treatment laboratory findings as follows; HBV DNA less than 9log copies per ml and ALT more than 2 times ULN in HBeAg positive patients, HBV DNA less than 7log copies per ml and elevated ALT in HBeAg negative patients Exclusion Criteria: 1.Documented co-infection with HCV, HIV at the beginning of LAM treatment 2.Decompensated liver cirrhosis at the beginning of LAM treatment 3.HCC at the beginning of LAM treatment","detailed_description":"This is to evaluate the proportion of subjects who show good responses to LAM treatment such as HBV DNA negativity, HBV DNA less than 4 log, no resistant mutation, HBeAg seroconversion and normalization of ALT in naïve CHB patients with certain pre-treatment characteristics, i.e. HBV DNA less than 9log copies per ml and ALT more than 2 times ULN in HBeAg positive subjects, HBV DNA less than 7log copies per ml and elevated ALT in HBeAg negative subjects.","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"N/A","display_phase_internal":"PHASE_NA","display_status":"Finalized","display_status_internal":"RECSTATUS_O_COMPLETED","endpoint":"","enrollment":"1","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"803f1d1c-b787-53ac-bc87-ae4c96718259","internal":{"content":null,"contentDigest":"014ec94983f91c496341cf6c5cc565b9","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: 1.CHB or liver cirrhosis due to Hepatitis B virus who had started LAM between Jan 1, 2003 and Dec 31, 2004 and maintained LAM at least 6 months 2.HBsAg positive at least for 6 months at the beginning of observation 3.HBV DNA positive before LAM administration 4.Subjects with certain pre-treatment laboratory findings as follows; HBV DNA less than 9log copies per ml and ALT more than 2 times ULN in HBeAg positive patients, HBV DNA less than 7log copies per ml and elevated ALT in HBeAg negative patients Exclusion Criteria: 1.Documented co-infection with HCV, HIV at the beginning of LAM treatment 2.Decompensated liver cirrhosis at the beginning of LAM treatment 3.HCC at the beginning of LAM treatment","interventions":[{"arm_group_label":"CHB patients who started LAM as an initial antiviral treatment","intervention_description":"This study is retrospective chart review","intervention_name":"No intervention","intervention_type":"Other"}],"interventional_subtype":"","is_fda_regulated":false,"is_high_value":false,"is_ind_study":false,"keywords":["retrospective","naïve Chronic Hepatitis B (CHB) patients","cohort study","lamivudine"],"last_follow_up_date":"06/30/2011 00:00:00","links":[],"locations":[{"City":"Kangwon-do","Latitude":"37.8228","CountryDisplay":"South Korea","Longitude":"128.1555","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"220-701","StatusDisplay":"Not yet recruiting","StatusDisplayInternal":"LOCSTATUS_NOT_YET_REC","StatusMapped":"Will Be Recruiting"},{"City":"Kangwon-do","Latitude":"37.8228","CountryDisplay":"South Korea","Longitude":"128.1555","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"220-70","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"","maximum_age_raw":"N/A","maximum_age":"N/A","minimum_age":"20","minimum_age_raw":"20 years","modified_date":"10/01/2018 22:26:29","number_of_arms":"","observational_design":{"biospecimen_description":"","biospecimen_retention":"None Retained","number_of_groups":"1","observational_study_design":"Cohort","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":"Retrospective"},"official_title":"A retrospective cohort study to evaluate the rate of good responses to lamivudine (LAM) treatment in naïve Chronic Hepatitis B (CHB) patients with certain pre-treatment characteristics","org_study_id":"113973","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"N/A","primary_compl_date":"06/30/2011 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Proportion of subjects showing HBV DNA negativity at 5 years of LAM treatment","outcome_time_frame":"5years","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Proportion of subjects showing HBV DNA negativity during first 4 years of LAM treatment","outcome_time_frame":"4 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Proportion of subjects showing HBV DNA less than 4 log copies per ml during 5 years of LAM treatment","outcome_time_frame":"5 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Cumulative proportion of subjects showing HBeAg seroconversion during 5 years of LAM treatment","outcome_time_frame":"5 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Cumulative proportion of subjects showing HBeAg loss during 5 years of LAM treatment","outcome_time_frame":"5 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Proportion of subjects showing ALT normalization during 5 years of LAM treatment","outcome_time_frame":"5 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Cumulative proportion of subjects showing resistant mutation during 5 years of LAM treatment","outcome_time_frame":"5 years","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GSK"]},"start_date":"08/13/2010 00:00:00","study_type":"Observational","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":null}},"pageContext":{"studyId":"113973"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}